---
title: "300142.SZ (300142.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300142.SZ/news.md"
symbol: "300142.SZ"
name: "300142.SZ"
parent: "https://longbridge.com/en/quote/300142.SZ.md"
datetime: "2026-05-21T02:51:42.089Z"
locales:
  - [en](https://longbridge.com/en/quote/300142.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300142.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300142.SZ/news.md)
---

# 300142.SZ (300142.SZ) — Related News

### [WALVAX "Breaking the Circle" Record: Vaccine Going Global 2.0 Combined with Synthetic Biology Track, Restructuring Growth Logic](https://longbridge.com/en/news/287043989.md)
*2026-05-20T09:54:07.000Z*
> WALVAX is accelerating its transformation, planning to reconstruct its growth logic through the internationalization of 

### [Vaccine sector stocks have collectively surged, with some funds entering during the low period to "buy the dip."](https://longbridge.com/en/news/285936446.md)
*2026-05-11T11:43:16.000Z*
> On May 11th, the vaccine sector saw a general rise in stock prices, with WALVAX hitting the limit up, and companies such

### [Corporate Innovation Intelligence (May 10): Huolala makes another push for Hong Kong Stock Exchange IPO as commission rates continue to decline](https://longbridge.com/en/news/285825129.md)
*2026-05-10T01:30:58.000Z*
> Huolala is once again sprinting for an IPO on the Hong Kong Stock Exchange, with commission rates continuing to decline.

### [Cardiovascular and antiviral drug developer Kejun Pharmaceutical has secured over 300 million yuan in Series C financing led by WALVAX](https://longbridge.com/en/news/285791062.md)
*2026-05-09T02:27:22.000Z*
> Cardiovascular and antiviral drug developer Kejun Pharmaceutical has completed over 300 million yuan in Series C financi

### [Receive subsidies, trade stocks, turn losses into profits! WALVAX: Main business is still bleeding](https://longbridge.com/en/news/284757754.md)
*2026-04-30T10:08:12.000Z*
> WALVAX's operating revenue in 2025 was 2.42 billion yuan, a year-on-year decrease of 14.3%, but the net profit attributa

### ["A-Share Focus" Pharmaceutical leader reports good performance, drug stocks boosted, Asymchem hits the upper limit](https://longbridge.com/en/news/284295925.md)
*2026-04-28T02:04:00.000Z*
> Pharmaceutical leader WuXi AppTec released its first-quarter report, with revenue of 12.436 billion yuan, a year-on-year

### [](https://longbridge.com/en/news/284289407.md)
*2026-04-28T01:07:34.000Z*
> The National Space Administration held a roundtable meeting on the high-quality development of commercial aerospace and 

### [Pre-market announcement gold mining: Highest over 130 times! Multiple stocks' net profit in the first quarter increased by more than 10 times year-on-year; Dynagreen signed a deepening cooperation framework agreement with Alibaba Cloud, CATL plans to place H shares to raise HKD 39.1 billion, and CAPCHEM invests 350 million to build the LiFSI project](https://longbridge.com/en/news/284286625.md)
*2026-04-28T00:47:20.000Z*
> This announcement involves the performance and investment plans of multiple companies. BBWPORT is investing CNY 3.095 bi

### [WALVAX: Net profit in the first quarter increased by 4082.41% year-on-year](https://longbridge.com/en/news/284186141.md)
*2026-04-27T09:27:20.000Z*
> WALVAX achieved operating revenue of 444 million yuan in the first quarter of 2026, a year-on-year decrease of 3.98%; ne